Widespread parainflammation in human cancer

Dvir Aran; Audrey Lasry; Adar Zinger; Moshe Biton; Eli Pikarsky; Asaf Hellman; Atul J. Butte; Yinon Ben-Neriah

doi:10.1186/s13059-016-0995-z

Widespread parainflammation in human cancer

Dvir Aran, Audrey Lasry, Adar Zinger, Moshe Biton, Eli Pikarsky, Asaf Hellman, Atul J. Butte^*, Yinon Ben-Neriah

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

72 Scopus citations

Abstract

Background: Chronic inflammation has been recognized as one of the hallmarks of cancer. We recently showed that parainflammation, a unique variant of inflammation between homeostasis and chronic inflammation, strongly promotes mouse gut tumorigenesis upon p53 loss. Here we explore the prevalence of parainflammation in human cancer and determine its relationship to certain molecular and clinical parameters affecting treatment and prognosis. Results: We generated a transcriptome signature to identify parainflammation in many primary human tumors and carcinoma cell lines as distinct from their normal tissue counterparts and the tumor microenvironment and show that parainflammation-positive tumors are enriched for p53 mutations and associated with poor prognosis. Non-steroidal anti-inflammatory drug (NSAID) treatment suppresses parainflammation in both murine and human cancers, possibly explaining a protective effect of NSAIDs against cancer. Conclusions: We conclude that parainflammation, a low-grade form of inflammation, is widely prevalent in human cancer, particularly in cancer types commonly harboring p53 mutations. Our data suggest that parainflammation may be a driver for p53 mutagenesis and a guide for cancer prevention by NSAID treatment.

Original language	English
Article number	145
Journal	Genome Biology
Volume	17
Issue number	1
DOIs	https://doi.org/10.1186/s13059-016-0995-z
State	Published - 8 Jul 2016

Bibliographical note

Funding Information:
This work was supported by the Gruss Lipper Postdoctoral Fellowship to D.A., grants from the Israel Science Foundation (ISF)—Centers of Excellence and the European Research Council within the FP-7 to YB-N (294390 PICHO) and EP (281738 LIVERMICROENV), the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF), the I-CORE program of ISF (grant number 41/11) and the Israel Cancer Research fund to Y.B.N., and Israel Science Foundation grant number 1162/12, I-CORE Program of the Planning and Budgeting Committee and the Israel Science Foundation grant number 41/11, and the Rosetrees Trust grant to A.H and the National Cancer Institute of the National Institutes of Health U24 CA195858 to A.J.B.

Publisher Copyright:
© 2016 The Author(s).

Keywords

Cancer prevention
Genomics
Inflammation
NSAID treatment
P53 mutations
Parainflammation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1186/s13059-016-0995-z

Cite this

@article{d101056a816d4acf8564fcad5b089fd9,

title = "Widespread parainflammation in human cancer",

abstract = "Background: Chronic inflammation has been recognized as one of the hallmarks of cancer. We recently showed that parainflammation, a unique variant of inflammation between homeostasis and chronic inflammation, strongly promotes mouse gut tumorigenesis upon p53 loss. Here we explore the prevalence of parainflammation in human cancer and determine its relationship to certain molecular and clinical parameters affecting treatment and prognosis. Results: We generated a transcriptome signature to identify parainflammation in many primary human tumors and carcinoma cell lines as distinct from their normal tissue counterparts and the tumor microenvironment and show that parainflammation-positive tumors are enriched for p53 mutations and associated with poor prognosis. Non-steroidal anti-inflammatory drug (NSAID) treatment suppresses parainflammation in both murine and human cancers, possibly explaining a protective effect of NSAIDs against cancer. Conclusions: We conclude that parainflammation, a low-grade form of inflammation, is widely prevalent in human cancer, particularly in cancer types commonly harboring p53 mutations. Our data suggest that parainflammation may be a driver for p53 mutagenesis and a guide for cancer prevention by NSAID treatment.",

keywords = "Cancer prevention, Genomics, Inflammation, NSAID treatment, P53 mutations, Parainflammation",

author = "Dvir Aran and Audrey Lasry and Adar Zinger and Moshe Biton and Eli Pikarsky and Asaf Hellman and Butte, {Atul J.} and Yinon Ben-Neriah",

note = "Publisher Copyright: {\textcopyright} 2016 The Author(s).",

year = "2016",

month = jul,

day = "8",

doi = "10.1186/s13059-016-0995-z",

language = "אנגלית",

volume = "17",

journal = "Genome Biology",

issn = "1474-7596",

publisher = "BioMed Central Ltd.",

number = "1",

}

TY - JOUR

T1 - Widespread parainflammation in human cancer

AU - Aran, Dvir

AU - Lasry, Audrey

AU - Zinger, Adar

AU - Biton, Moshe

AU - Pikarsky, Eli

AU - Hellman, Asaf

AU - Butte, Atul J.

AU - Ben-Neriah, Yinon

PY - 2016/7/8

Y1 - 2016/7/8

N2 - Background: Chronic inflammation has been recognized as one of the hallmarks of cancer. We recently showed that parainflammation, a unique variant of inflammation between homeostasis and chronic inflammation, strongly promotes mouse gut tumorigenesis upon p53 loss. Here we explore the prevalence of parainflammation in human cancer and determine its relationship to certain molecular and clinical parameters affecting treatment and prognosis. Results: We generated a transcriptome signature to identify parainflammation in many primary human tumors and carcinoma cell lines as distinct from their normal tissue counterparts and the tumor microenvironment and show that parainflammation-positive tumors are enriched for p53 mutations and associated with poor prognosis. Non-steroidal anti-inflammatory drug (NSAID) treatment suppresses parainflammation in both murine and human cancers, possibly explaining a protective effect of NSAIDs against cancer. Conclusions: We conclude that parainflammation, a low-grade form of inflammation, is widely prevalent in human cancer, particularly in cancer types commonly harboring p53 mutations. Our data suggest that parainflammation may be a driver for p53 mutagenesis and a guide for cancer prevention by NSAID treatment.

AB - Background: Chronic inflammation has been recognized as one of the hallmarks of cancer. We recently showed that parainflammation, a unique variant of inflammation between homeostasis and chronic inflammation, strongly promotes mouse gut tumorigenesis upon p53 loss. Here we explore the prevalence of parainflammation in human cancer and determine its relationship to certain molecular and clinical parameters affecting treatment and prognosis. Results: We generated a transcriptome signature to identify parainflammation in many primary human tumors and carcinoma cell lines as distinct from their normal tissue counterparts and the tumor microenvironment and show that parainflammation-positive tumors are enriched for p53 mutations and associated with poor prognosis. Non-steroidal anti-inflammatory drug (NSAID) treatment suppresses parainflammation in both murine and human cancers, possibly explaining a protective effect of NSAIDs against cancer. Conclusions: We conclude that parainflammation, a low-grade form of inflammation, is widely prevalent in human cancer, particularly in cancer types commonly harboring p53 mutations. Our data suggest that parainflammation may be a driver for p53 mutagenesis and a guide for cancer prevention by NSAID treatment.

KW - Cancer prevention

KW - Genomics

KW - Inflammation

KW - NSAID treatment

KW - P53 mutations

KW - Parainflammation

UR - http://www.scopus.com/inward/record.url?scp=84977617228&partnerID=8YFLogxK

U2 - 10.1186/s13059-016-0995-z

DO - 10.1186/s13059-016-0995-z

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 27386949

AN - SCOPUS:84977617228

SN - 1474-7596

VL - 17

JO - Genome Biology

JF - Genome Biology

IS - 1

M1 - 145

ER -

Widespread parainflammation in human cancer

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this